Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Guy Gadois who wrote (1271)	2/1/1999 7:39:00 AM
From: Captain Jack	Respond to of 1510

Jon--- I agree and believe 15 is not going to be that difficult anyway. A little time and just a tiny bit of good news and it will go all by itself...

To: Guy Gadois who wrote (1271)	2/2/1999 8:07:00 AM
From: Captain Jack	Read Replies (2) \| Respond to of 1510

A nice wake up--- biz.yahoo.com The Immune Response Corporation Receives U.S. Patent for the Treatment of T Cell Cancers CARLSBAD, Calif., Feb. 2 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today announced that it has received a patent from the United States Patent and Trademark Office entitled Vaccination and Methods Against Diseases Resulting from Pathogenic Responses by Specific T Cell Populations. The patent, Number 05861164, extends previous coverage for the Company's T cell receptor vaccine technology to the treatment of diseases mediated by unregulated clonal replication (e.g., T cell lymphoma). The patent covers the selection and use of T cell receptors present on malignant T cells as vaccines to treat T cell cancers. The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T cell responses for the treatment of HIV, autoimmune diseases, and cancer. The Company is conducting clinical trials for its immune-based therapies for HIV, rheumatoid arthritis, psoriasis, multiple sclerosis, colon cancer and brain cancer, and preclinical studies for melanoma and prostate cancers. In addition, the Company is developing a targeted delivery technology for gene therapy which is designed to enable the intravenous injection of genes for delivery directly to the liver. The Company's gene therapy program is currently focused on diseases of the liver and is in preclinical studies for the treatment of hemophilia and hepatitis. NOTE: The Immune Response Corporation news releases are available at no charge through the company's automated attendant 800 number at 800-491-0153. News releases are also available through PR Newswire's Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: imnr.com. This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including the uncertainty of successful completion of clinical trials, and those risks set forth from time to time in The Immune Response Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1997. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. SOURCE: The Immune Response Corporation